Based on the OptiNose stock forecast from 3 analysts, the average analyst target price for OptiNose is USD 12.40 over the next 12 months. OptiNose’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of OptiNose is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, OptiNose’s stock price was USD 9.28. OptiNose’s stock price has changed by +1.20% over the past week, +1.20% over the past month and -31.64% over the last year.
No recent analyst target price found for OptiNose
No recent average analyst rating found for OptiNose
Company Overview OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. Read Less
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exh...Read More
Frequently Asked Questions About OptiNose (OPTN) Stock
Based on ratings from 3 analysts OptiNose's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on OPTN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for OPTN is USD 12.40 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 9.
OPTN stock's Price/Earning ratio is 57.00.
Our analysis grades OPTN stock's Price / Earning ratio at F. This means that OPTN stock's Price/Earning ratio is above 70% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this OPTN may be a overvalued for its sector.
The last closing price of OPTN's stock was USD 9.28.
The most recent market capitalization for OPTN is USD 0.09B.
Based on targets from 3 analysts, the average taret price for OPTN is projected at USD 12.40 over the next 12 months.
This means that OPTN's stock price may go up by +33.62% over the next 12 months.
We can't find any ETFs which contains OptiNose's stock.
As per our most recent records OptiNose has 127 Employees.
OptiNose's registered address is 777 Township Line Road, Yardley, PA, United States, 19067.
You can get more information about it from OptiNose's website at https://www.optinose.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About OptiNose (OPTN) Stock
Based on ratings from 3 analysts OptiNose's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 3 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on OPTN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for OPTN is USD 12.40 over the next 12 months. The maximum analyst target price is USD 18 while the minimum anlayst target price is USD 9.
OPTN stock's Price/Earning ratio is 57.00.
Our analysis grades OPTN stock's Price / Earning ratio at F. This means that OPTN stock's Price/Earning ratio is above 70% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this OPTN may be a overvalued for its sector.
The last closing price of OPTN's stock was USD 9.28.
The most recent market capitalization for OPTN is USD 0.09B.
Based on targets from 3 analysts, the average taret price for OPTN is projected at USD 12.40 over the next 12 months.
This means that OPTN's stock price may go up by +33.62% over the next 12 months.
We can't find any ETFs which contains OptiNose's stock.
As per our most recent records OptiNose has 127 Employees.
OptiNose's registered address is 777 Township Line Road, Yardley, PA, United States, 19067.
You can get more information about it from OptiNose's website at https://www.optinose.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for OPTN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
